- Home
- SNGX vs ADTX Comparison
SNGX vs ADTX Comparison
Compare SNGX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- ADTX
- Stock Information
- Founded
- SNGX 1987
- ADTX 2017
- Country
- SNGX United States
- ADTX United States
- Employees
- SNGX N/A
- ADTX N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- ADTX Health Care
- Exchange
- SNGX Nasdaq
- ADTX Nasdaq
- Market Cap
- SNGX 6.5M
- ADTX 5.3M
- IPO Year
- SNGX 1987
- ADTX 2020
- Fundamental
- Price
- SNGX $1.89
- ADTX $1.48
- Analyst Decision
- SNGX
- ADTX
- Analyst Count
- SNGX 0
- ADTX 0
- Target Price
- SNGX N/A
- ADTX N/A
- AVG Volume (30 Days)
- SNGX 18.7K
- ADTX 197.4K
- Earning Date
- SNGX 05-09-2025
- ADTX 05-15-2025
- Dividend Yield
- SNGX N/A
- ADTX N/A
- EPS Growth
- SNGX N/A
- ADTX N/A
- EPS
- SNGX N/A
- ADTX N/A
- Revenue
- SNGX $2,342.00
- ADTX $55,323.00
- Revenue This Year
- SNGX N/A
- ADTX $15,768.94
- Revenue Next Year
- SNGX N/A
- ADTX N/A
- P/E Ratio
- SNGX N/A
- ADTX N/A
- Revenue Growth
- SNGX N/A
- ADTX N/A
- 52 Week Low
- SNGX $1.68
- ADTX $1.47
- 52 Week High
- SNGX $14.83
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- SNGX 45.39
- ADTX 29.47
- Support Level
- SNGX $1.85
- ADTX $1.65
- Resistance Level
- SNGX $1.95
- ADTX $1.83
- Average True Range (ATR)
- SNGX 0.09
- ADTX 0.12
- MACD
- SNGX 0.01
- ADTX 0.18
- Stochastic Oscillator
- SNGX 42.11
- ADTX 2.63
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.